Clinical Trials Arena June 20, 2024
Gilead’s share price jumped by 5.7% following the announcement that its Phase III trial of lenacapavir met its primary endpoint.
Gilead has announced topline results from an interim analysis of its Phase III PURPOSE 1 trial showing that its HIV drug Sunlenca (lenacapavir), prevented 100% of HIV cases in cisgender women.
The trial (NCT04994509) involved women and female adolescents aged between 16 and 25 years in South Africa and Uganda, some of whom received Gilead’s Sunlenca, and others who received Gilead’s other once-daily drugs like Truvada (emtricitabine/tenofovir disoproxil fumarate) or Descovy (emtricitabine/tenofovir alafenamide). The trial met its primary endpoint, showing clear superiority of Sunlenca to once-daily oral Truvada and background HIV (bHIV) for HIV prevention in cisgender women.
...Today's Sponsors
Today's Sponsor